tiprankstipranks
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Switzerland Market
SANN
Santhera Pharmaceuticals Holding
RESEARCH TOOLSreports
Want to see CH:SANN full AI Analyst Report?

Santhera Pharmaceuticals Holding (SANN) Earnings Dates, Call Summary & Reports

5 Followers

Earnings Data

Report Date
Sep 21, 2026
TBA (Not Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.09
Last Year’s EPS
-3.04
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Sep 23, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.
Company Guidance
During the Santhera Pharmaceuticals half-year results call for the fiscal year 2025, Catherine Isted, the CFO, provided key financial guidance and metrics. The company announced new financing of CHF 20 million, extending their runway to cash flow breakeven by mid-2026. Santhera's cash balance was CHF 18.4 million as of June 30, 2025. The company's global sales reached over $100 million, and they expect full-year revenues to exceed CHF 65-70 million. Sales from their U.S. partner, Catalyst, were USD 49.4 million in H1 2025, with a full-year forecast of $100-110 million. This could trigger a $12.5 million milestone payment. Additionally, they anticipate strong growth in China following Sperogenix's commercial rollout, with over 250 patients already on AGAMREE. Santhera is expanding its market presence with recent launches in the U.K. and other European countries, aiming for a market size exceeding $600 million, including potential revenues from Europe, North America, and China as well as distribution agreements in other regions.
Strong AGAMREE Adoption in Key Markets
AGAMREE has achieved approximately 40% market share of steroid using DMD patients in Germany and Austria, with Austria exceeding 50% market share.
U.S. Market Performance
Catalyst reported H1 2025 sales of USD 49.4 million, on track to meet the full-year guidance of $100 million to $110 million, which would trigger a $12.5 million milestone payment to Santhera.
Successful Commercial Rollout in China
Sperogenix commenced non-reimbursed commercial rollout in China with over 250 patients, representing significant growth potential.
Increased Revenue Guidance
Santhera increased its revenue guidance for 2025, expecting revenues to exceed CHF 65 million to CHF 70 million due to strong market performances.

Santhera Pharmaceuticals Holding (CH:SANN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

CH:SANN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 21, 2026
2026 (Q2)
-0.09 / -
-3.04―――
Apr 28, 2026
2025 (Q4)
-0.43 / -0.43
-0.7441.89% (+0.31)
Sep 23, 2025
2025 (Q2)
-0.60 / -3.04
-1.35-125.19% (-1.69)
Apr 29, 2025
2024 (Q4)
-0.74 / -0.74
7.27-110.18% (-8.01)
Sep 12, 2024
2024 (Q2)
-0.94 / -1.35
-1.5814.56% (+0.23)―
Apr 25, 2024
2023 (Q4)
- / 7.27
-2.13441.31% (+9.40)―
Sep 07, 2023
2023 (Q2)
-1.58 / -1.58
-5.2469.85% (+3.66)――
Apr 27, 2023
2022 (Q4)
- / -2.13
-2.37.39% (+0.17)――
Oct 31, 2022
2022 (Q2)
- / -5.24
-9.22443.19% (+3.98)――
Mar 11, 2022
2021 (Q4)
-6.01 / -7.60
-23.01166.97% (+15.41)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CH:SANN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 28, 2026
CHF18.36CHF18.54+0.98%
Sep 23, 2025
CHF13.86CHF11.90-14.14%
Apr 29, 2025
CHF15.28CHF14.80-3.14%
Sep 12, 2024
CHF9.76CHF8.90-8.81%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Santhera Pharmaceuticals Holding (CH:SANN) report earnings?
Santhera Pharmaceuticals Holding (CH:SANN) is schdueled to report earning on Sep 21, 2026, TBA (Not Confirmed).
    What is Santhera Pharmaceuticals Holding (CH:SANN) earnings time?
    Santhera Pharmaceuticals Holding (CH:SANN) earnings time is at Sep 21, 2026, TBA (Not Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Santhera Pharmaceuticals Holding stock?
          The P/E ratio of Santhera Pharmaceuticals Holding is N/A.
            What is CH:SANN EPS forecast?
            CH:SANN EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.